UCLA turns cord blood into off-the-shelf cancer T cells — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UCLA researchers developed AlloESO-T cells from cord blood stem cells that target solid tumors through both a T-cell receptor against NY-ESO-1 and a natural killer cell receptor backup system designed to counter antigen escape.
- In mouse models of ovarian cancer and melanoma, a single dose of AlloESO-T produced lasting tumor control and extended survival, while comparison cells made from mature donor T cells caused graft-versus-host disease and only partial tumor control.
- Starting with cord blood stem cells rather than mature donor T cells meant the engineered cells carried only the inserted cancer-targeting receptor, eliminating the random native receptors that can attack healthy tissue and removing the need for additional gene editing.
- A small supply of cord blood stem cells can yield trillions of therapeutic cells within about six weeks — enough for thousands of doses at an estimated $5,000 per dose, the researchers said, versus hundreds of thousands of dollars for personalized T-cell treatments.
- Yanruide (Charlie) Li, co-senior author and a postdoctoral scholar in the Yang lab, framed AlloESO-T as a modular platform: "As long as a receptor for a given cancer antigen has been validated, we can build it into this system."
- The treatment has been tested only in preclinical mouse experiments; it has not entered human clinical trials and has not been approved by the FDA.
Why it matters: A single-dose, off-the-shelf TCR therapy at an estimated $5,000 per dose would cost a fraction of current personalized T-cell treatments that run into six figures. By building the cells from cord blood stem cells and layering in an NK-receptor backup against antigen escape, the UCLA team addresses the two roadblocks — cost and graft-versus-host disease — that have kept donor-derived T-cell therapy out of solid tumors.
Ask SkimNews
